نتائج البحث - Sai‐Hong Ignatius Ou

تنقيح النتائج
  1. 1
    Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond

    Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond حسب Sai‐Hong Ignatius Ou

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer

    Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer حسب Sai‐Hong Ignatius Ou, Jason A. Zell

    منشور في 2008
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Validation Study of the Proposed IASLC Staging Revisions of the T4 and M Non-small Cell Lung Cancer Descriptors Using Data from 23,583 Patients in the California Cancer Registry

    Validation Study of the Proposed IASLC Staging Revisions of the T4 and M Non-small Cell Lung Cancer Descriptors Using Data from 23,583 Patients in the California Cancer Registry حسب Sai‐Hong Ignatius Ou, Jason A. Zell

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies

    Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies حسب Sai‐Hong Ignatius Ou, Jason A. Zell

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition

    The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition حسب Sai‐Hong Ignatius Ou, Jason A. Zell

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020

    Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020 حسب Sai‐Hong Ignatius Ou, Viola W. Zhu

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno

    Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno حسب Danielle Brazel, Sai‐Hong Ignatius Ou, Misako Nagasaka

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Taletrectinib for the treatment of <i>ROS-1</i> positive non-small cell lung cancer: a drug evaluation of phase I and II data

    Taletrectinib for the treatment of <i>ROS-1</i> positive non-small cell lung cancer: a drug evaluation of phase I and II data حسب Misako Nagasaka, Danielle Brazel, Sai‐Hong Ignatius Ou

    منشور في 2024
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Asian Ethnicity Is a Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer (NSCLC) and Is Independent of Smoking Status

    Asian Ethnicity Is a Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer (NSCLC) and Is Independent of Smoking Status حسب Sai‐Hong Ignatius Ou, Argyrios Ziogas, Jason A. Zell

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Prognostic Factors for Survival in Extensive Stage Small Cell Lung Cancer (ED-SCLC): The Importance of Smoking History, Socioeconomic and Marital Statuses, and Ethnicity

    Prognostic Factors for Survival in Extensive Stage Small Cell Lung Cancer (ED-SCLC): The Importance of Smoking History, Socioeconomic and Marital Statuses, and Ethnicity حسب Sai‐Hong Ignatius Ou, Argyrios Ziogas, Jason A. Zell

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Liquid Biopsy to Identify Actionable Genomic Alterations

    Liquid Biopsy to Identify Actionable Genomic Alterations حسب Sai‐Hong Ignatius Ou, Misako Nagasaka, Viola W. Zhu

    منشور في 2018
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020

    Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020 حسب Sai‐Hong Ignatius Ou, Viola W. Zhu, Misako Nagasaka

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC

    From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC حسب Sai‐Hong Ignatius Ou, Alexandria TM Lee, Misako Nagasaka

    منشور في 2023
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC

    Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC حسب Zhaohui Arter, Kevin Shieh, Misako Nagasaka, Sai‐Hong Ignatius Ou

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

    Targeting MET in Lung Cancer: Will Expectations Finally Be MET? حسب Alexander Drilon, Federico Cappuzzo, Sai‐Hong Ignatius Ou, D. Ross Camidge

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable

    The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable حسب Thanyanan Reungwetwattana, Ying Liang, Viola W. Zhu, Sai‐Hong Ignatius Ou

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC

    Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC حسب Shannon Zhang, Misako Nagasaka, Viola W. Zhu, Sai‐Hong Ignatius Ou

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer

    Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer حسب Leow Pay Chin, Ross A. Soo, Richie Soong, Sai‐Hong Ignatius Ou

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib

    Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib حسب Sai‐Hong Ignatius Ou, Michele C. Azada, Joni Dy, Jonathan A. Stiber

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Alectinib Induces a Durable (&amp;gt;15 Months) Complete Response in an <i>ALK</i>-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis

    Alectinib Induces a Durable (&amp;gt;15 Months) Complete Response in an <i>ALK</i>-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomening... حسب Sai‐Hong Ignatius Ou, Karen R. Sommers, Michele C. Azada, Edward B. Garon

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: